Statement: In the primary trial patient cohort, 3 different types of infections are observed. 
Primary_evidence: Adverse Events 1:   Total: 14/41 (34.15%)   Cardiac ischemia/infarction 2/41 (4.88%)   Duodenal ulcer 1/41 (2.44%)   Vomiting 2/41 (4.88%)   Fever 2/41 (4.88%)   Death NOS 1/41 (2.44%)   Liver failure 1/41 (2.44%)   Infection - pneumonia 2/41 (4.88%)   Infection - port site 2/41 (4.88%)   Infection - urinary tract 1/41 (2.44%)   Disease progression 3/41 (7.32%)   Confusion 1/41 (2.44%)